From: www.ecancer.tv on Tue, Jul 20 2010 1:56 PM

Dr Beatty discusses his research into the use of the CD40 agonist monoclonal antibody CP-870,893 to treat pancreatic cancer. When used in conjunction with the gemcitabine, this antibody targets the immune system and causes it to seek out and fight the cancer, increasing progression free survival...

From: www.ecancer.tv on Tue, Jul 20 2010 1:56 PM

Prof Salles discusses the results he is presenting at ASCO 2010 from the PRIMA study. This trial assessed the efficacy of rituximab as a maintenance treatment for patients with follicular lymphoma. This study found a 50% reduction in recurrence in patients treated with rituximab.

From: www.ecancer.tv on Fri, Jul 16 2010 6:15 AM

Dr Stewart discusses results of Phase I and Phase II trials of carfilzomib, a next generation proteasome inhibitor, which has a different binding structure to bortezomib.This interview is supported by an unrestricted educational grant from Novartis Oncology.

From: www.ecancer.tv on Fri, Jul 16 2010 6:15 AM

Dr Evangelos Terpos, speaking at EHA 2010, discusses bone disease in multiple myeloma and the targeted therapies for treatment and prevention of skeletal related events.This interview is supported by an unrestricted educational grant from Novartis Oncology.

From: www.ecancer.tv on Thu, Jul 15 2010 6:34 AM

Dr Elisabeth Pitterman, an Austrian delegate at ASCO Chicago 2010, gives her views and highlights of the joint ASCO-ASH education session. (In German)This interview is supported by a unrestricted educational grant from Mundipharma.

From: www.ecancer.tv on Thu, Jul 08 2010 1:52 PM

Dr Karim Fizazi discusses his phase III trial which compared the efficacy of denosumab with zoledronic acid in patients with matastatic castration-resistant prostate cancer. The trial demonstrated that denosumab is superior to zoledronic acid in delaying or preventing skeletal-related events. Dr ...

From: www.ecancer.tv on Thu, Jul 08 2010 11:02 AM

Data from the SUCCESS trial, presented at ASCO, looked at circulating tumour cells in primary breast cancer. Dr. Brigitte Rack talks to Prof Gordon McVie about the findings. This interview is supported by an unrestricted educational grant from Novartis Oncology.

From: www.ecancer.tv on Tue, Jul 06 2010 2:23 PM

Data presented at the Joint ASH/ASCO Educational Meeting suggested good results for new frontline treatments for various lymphomas. Prof. Bruce Cheson talks to Prof. Gordon McVie about the findings.This interview has been supported by a restricted grant from Mundipharma GmbH . Bendamustine is lic...

From: www.ecancer.tv on Wed, Jun 30 2010 2:15 PM

Healthcare experts discuss the care of the elderly in haemato-oncology, looking at the current situation across Europe and what is needed to change the treatment of older patients. This interview is supported by an unrestricted educational grant from Celgene.

From: www.ecancer.tv on Wed, Jun 30 2010 10:41 AM

A new study presented at ASCO has found that eribulin can extend the survival rates of women with locally recurrent or metastatic breast cancer in women who have already received extensive standard therapy. Prof Twelves who helped designed the trial talks to Prof McVie about the findings.Supporte...

From: www.ecancer.tv on Wed, Jun 30 2010 10:41 AM

Dr Le Chevalier speaks about the work carried out at the Gustave-Roussy Institute and the difficulties faced when treating lung cancer. In order to address some of these issues a new institute of thoracic oncology is being established to combine the expertise of both Gustave-Roussy Institute and ...

From: www.ecancer.tv on Wed, Jun 30 2010 10:41 AM

Prof David Cameron chairs a round table debate on clinical trial design and comparator arms. The discussion examines issues such as the need to fast forward drug evaluation of targeted agents, how to detect unpredictable side effects of targeted compounds and how fast can combinations be evaluat...

From: www.ecancer.tv on Wed, Jun 30 2010 10:41 AM

This roundtable discussion looks at the advantages and disadvantages of overall survival and progression free survival as primary end points of clinical trials. The discussants also talk about how the primary endpoints for clinical trials are decided and by whom.Supported by an educational grant ...

From: www.ecancer.tv on Tue, Jun 29 2010 7:36 AM

Prof Jassem talks about advances in the treatment of lung cancer and the number of options that are now available to patients. More effective and safer surgery allows more patients to be treated and advances in imaging techniques has made localised treatment possible at higher doses, increasing ...

From: www.ecancer.tv on Fri, Jun 25 2010 1:10 PM

Professor Ignace Vergote speaks about his research into NKTR-102, a new drug for treating women with platinum-resistant/refractory ovarian cancer. In addition to the encouraging results of this trial, the study has found that that NKTR-102 only has limited side effects. Prof Vergote’s team will ...

From: www.ecancer.tv on Fri, Jun 25 2010 1:09 PM

Prof Richard Sullivan talks about a collaborative initiative to push the issue of cancer and the elderly up the social-political agenda. He suggests reasons for why older patients receive inadequate treatment and what needs to be done to improve the situation.

From: www.ecancer.tv on Fri, Jun 25 2010 1:09 PM

Results of a multiple myeloma study, presented at ASCO, has found that zoledronic acid (Zometa) reduces the incidence of skeletal related events and improves overall survival and progression free survival, when compared to clodronate. Prof Gareth Morgan talks to Prof Gordon McVie about the findi...

From: www.ecancer.tv on Fri, Jun 25 2010 1:09 PM

Although it is known that rituximab (trade name Rituxan) should be used in combination with chemotherapy to treat patients with indolent lymphoma diseases, there has been no research to demonstrate which chemotherapy regimen was the most effective. Dr Rummel outlines the results of a randomised ...

From: www.ecancer.tv on Fri, Jun 25 2010 1:09 PM

Prof Jesús San-Miguel, speaking to Prof Gordon McVie, talks about the progression in myeloma survival rates and the contributing factors. Data from a large randomised trial is showing that zoledronic acid compared to oral clodronate is superior in preventing skeletal complications and i...

From: www.ecancer.tv on Fri, Jun 25 2010 1:09 PM

Jan Geissler talks about the issue of ageism in cancer treatment, discussing the reasons why older patients don’t appear to receive as good a treatment as younger patients. He also suggests ways in which the problem can be tackled.